title: Tenofovir-associated proteinuria.
abstract: Proteinuria was observed in 27% of 153 patients taking tenofovir for more than 1 year. Concomitant protease inhibitor therapy and cumulative tenofovir exposure were independently associated with proteinuria in this cohort. Proteinuria was reversible in 11 of 12 patients who ceased tenofovir because of proteinuria without altering other medications. Clinicians should be aware that tenofovir can cause reversible proteinuria in patients with HIV.
authors.affiliation: Brisbane Sexual Health and HIV Service, Brisbane, Queensland, Australia. mark_d_kelly@health.qld.gov.au
authors.forename: Mark D
authors.initials: MD
authors.lastname: Kelly
authors.forename: Abby
authors.initials: A
authors.lastname: Gibson
authors.forename: Harry
authors.initials: H
authors.lastname: Bartlett
authors.forename: Diane
authors.initials: D
authors.lastname: Rowling
authors.forename: John
authors.initials: J
authors.lastname: Patten
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003401:Creatine / Q000652:urine*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D011507:Proteinuria / Q000139:chemically induced* / Q000652:urine; D051436:Renal Insufficiency, Chronic / Q000139:chemically induced* / Q000652:urine; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine; D003401:Creatine